论文部分内容阅读
目的：探讨普伐他汀促进动脉粥样硬化斑块消退的机制。方法：观察高胆固醇血症患者经普伐他汀１０～２０ｍｇ／ｄ治疗４周及８周后血小板功能和血脂的变化。结果：治疗４周及８周后血胆固醇降低，同时每个血小板膜表面Ｐ选择素的分子数由治疗前的７４８±１５４分别降至４７８±１１０和３７８±１１９；血浆Ｐ选择素由治疗前的２４．３±９．９μｇ／Ｌ分别降至１６．８±４．５和１６．１±４．０μｇ／Ｌ，血小板膜表面和血浆Ｐ选择素之间显示较好的相关性（ｒ＝０．８７２２）。结论：普伐他汀促进动脉粥样硬化斑块消退的早期效益是由于对血小板功能的良性影响而产生。
Objective: To investigate the mechanism of pravastatin on the regression of atherosclerotic plaque. Methods: The changes of platelet function and blood lipid in patients with hypercholesterolemia after pravastatin 10 ~ 20mg / d for 4 weeks and 8 weeks were observed. Results: After 4 weeks and 8 weeks of treatment, the blood cholesterol decreased. At the same time, the number of P-selectin on each platelet surface decreased from 748 ± 154 before treatment to 478 ± 110 and 378 ± 119 respectively. Plasma P-selectin 24.3 ± 9.9 μg / L before treatment decreased to 16.8 ± 4.5 and 16.1 ± 4.0 μg / L, respectively, showing a good correlation between platelet membrane surface and plasma Pselectin (R = 0.8722). Conclusions: The early benefit of pravastatin in promoting the regression of atherosclerotic plaques is due to the benign effect on platelet function.